Abstract: The present invention relates to the use of at least one dicyclohexylmethanol derivative of the formula (I) as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific dicyclohexylmethanol derivatives and to a process for the preparation thereof.

Abstract: Compounds of structure (I): including stereoisomers, tautomers and salts thereof, wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as defined herein. Such compounds are useful for the preparation of diarylpropane compounds. Methods for the preparation of compounds of structure (I) are also disclosed, as are methods employing compounds of structure (I) for the preparation of diarylpropanes.

Abstract: Provided is an optical film used for the optical compensation, in which additives are added to thereby have a good stability at high temperature and high humidity, a higher chromaticity, a higher Haze and a higher moisture resistance, as well as a small thickness direction retardation (Rth).

Abstract: Provided are methods for treating a pathological condition associated with unbalanced osteoclast differentiation by providing an AQP-9 modulator. The modulator can be an AQP-9 inhibitor or an AQP-9 inducer. Also provided are methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation, as well as pharmaceutical composition including such modulators.

Abstract: Bi- and tri-aromatic compounds of the formula (I) wherein R1 to RIO and X are as defined, are Nox2 inhibitors that are useful as medicaments for the treatment of a disease or condition selected from: cardiovascular diseases, respiratory diseases, inflammatory diseases, cancers, ageing and age related disorders, kidney diseases, neurodegenerative diseases, diabetes and conditions associated with diabetes. The compounds, their preparation and pharmaceutical compositions comprising them are disclosed.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1-R3 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.

Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.

Abstract: The invention provides a novel platform for minimal- or non-flammable polymers, which is based purely on hydrocarbon systems and does not need additives of any kind A key feature is that the hydrocarbons disclosed herein are characterized by degradation mechanisms that produce few flammable volatiles. For example, 2,4,4?,6-tetrahydroxydeoxybenzoin is employed as a multifunctional cross-linker in conjunction with bis-epoxydeoxybenzoin, affording new resins that combine excellent physical and mechanical properties with low flammability.

Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.

Abstract: The present invention provides methylene beta-diketone monomers, methods for producing the same, and compositions and products formed therefrom. In the method for producing the methylene beta-diketones of the invention, a beta-diketone is reacted with a source of formaldehyde in a modified Knoevenagel reaction optionally in the presence of an acidic or basic catalyst, and optionally in the presence of an acidic or non-acidic solvent, to form reaction complex. The reaction complex may be an oligomeric complex. The reaction complex is subjected to further processing, which may be vaporization by contact with an energy transfer means in order to isolate the beta-diketone monomer. The present invention further compositions and products formed from methylene beta-diketone monomers of the invention, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Abstract: Compounds of structure (I): including stereoisomers, tautomers and salts thereof, wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as defined herein. Such compounds are useful for the preparation of diarylpropane compounds. Methods for the preparation of compounds of structure (I) are also disclosed, as are methods employing compounds of structure (I) for the preparation of diarylpropanes.

Abstract: 4-Aralkylphenols and derivatives thereof expressed by general formulas (6) and (7) are useful for producing trisphenols.

Abstract: The present invention relates to substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound.

Abstract: A chemical compound of structural formula (I) useful in preparation of flame retardant materials is disclosed. Homopolymer, and copolymers of a compound of formula (I), as well as methods of preparing said homo- and copolymers are also disclosed. Polymers described herein advantageous possess low heat release capacities and high char yields.

Abstract: Compounds of formula (I): wherein R1 and R4 are OR7, R2 and R3 are H or OR7, with the proviso that when R2 is OR7 then R3 is H, and when R3 is OR7 then R2 is H; R5 and R6 are independently H, OH, or OR7 with the proviso that when R5 is OH, R6 is not OH; R7 is alkyl, aryl or arylalkyl; the drawing “” represents either a single or a double bond; or pharmaceutically acceptable salt(s) or prodrug(s) thereof. These compounds are useful of treatment, prophylaxis, amelioration, or defense against and/or prevention of hormonal dependent conditions, cancer, and diseases and conditions associated with oxidant stress.

Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.

Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.

Abstract: The invention pertains to novel oligofunctional photoinitiators of the formula (1) or (1A). R1 and R2 are methyl or together are —(CH2)5—; and n is 2 or 3, and the solvent in (1A) is water or an organic solvent; and their use in photopolymerizable compositions, in particular inks.

Abstract: Compounds of structure (I): including stereoisomers, tautomers and salts thereof, wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as defined herein. Such compounds are useful for the preparation of diarylpropane compounds. Methods for the preparation of compounds of structure (I) are also disclosed, as are methods employing compounds of structure (I) for the preparation of diarylpropanes.

Abstract: A description is given of (4-trifluoromethyl-3-thiobenzoyl)cyclohexanediones of the formula (I) and of their use as herbicides. In this formula (I), X, R1, R2, R3, and R4 are radicals such as hydrogen and organic radicals such as alkyl. A and Z are oxygen or alkylene.

Abstract: What is described are 3-aminocarbonyl-substituted benzoylcyclohexanediones of the formula (I) as herbicides. In this formula (I), R1 to R5 are radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. X is alkylene.

Abstract: The present invention discloses novel aromatic ketone compounds with functional substiution groups at para- or meta positions which can be used as photo-initiators or effective components of photo-initiator mixtures for the photopolymerizations of ethylenically unsaturated systems. The preparation of these compounds is also disclosed.

Abstract: The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The present invention also relates to the process of preparation of the said compounds.

Abstract: The ink composition of the invention is applied to a region to which a color ink composition has been applied. The ink composition contains a weather resistance enhancer, is substantially free from a colorant, and is applied to a recording medium to form a coating film exhibiting an integrated value of light transmittance of not more than 2000 for each nanometer at wavelengths of 320 nm to 360 nm and an integrated value of light transmittance of not less than 36000 for each nanometer at wavelengths of 380 nm to 780 nm.

Abstract: Photoactivatable prepolymers and methods of use thereof are disclosed for microencapsulation of a substantially water-insoluble material within a nonporous shell. As provided herein, the microencapsulated material is released with no more than a slow release rate. Upon exposure of the nonporous shell to light, the nonporous shell is converted into a porous shell having an increased release rate for the microencapsulated material.

Abstract: The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders.

Abstract: The present invention relates to the use of specific aldehydes or ketones of the formula I as photostabiliser for at least one compound to be stabilised. The invention furthermore relates to a method for the photostabilisation of a second compound by a compound of the formula I and to compositions comprising at least one compound of the formula I of this type.

Abstract: The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.

Abstract: The present invention relates to a conjugated aromatic compound represented by the Formula (1) in claim 1 (in the formula, Ar1 represents a hydrogen atom or an aryl group optionally having a substituent; Ar2 and Ar3 each represent a hydrogen atom or an aryl group optionally having a substituent but at least one of Ar2 and Ar3 represents an aryl group optionally having a substituent; and A represents an aromatic hydrocarbon group) and relates to an optical material containing the conjugated aromatic compound. The conjugated aromatic compound and the optical material have characteristics of a high chromatic aberration correction function, high refractive-index dispersion characteristics (Abbe number (vd)) and high secondary dispersion characteristics (?g,F) (anomalous dispersion characteristics).

Abstract: The invention relates to a process for preparing 2,4-dihydroxyphenyl 4-methoxybenzyl ketones of the formula (I) by Friedel-Crafts acylation in hydrogen fluoride (HF). 2,4-Dihydroxyphenyl 4-methoxybenzyl ketones of the formula (I) in which R1 and R2 are each hydrogen, chlorine, fluorine, bromine, iodine, CF3, methyl, optionally substituted alkoxy, —OCF3, —C(CH3)3, —CH2(CH3)2, —CH(CH3)2, R3 is hydrogen, Cl, F, Br, optionally substituted alkyl, optionally substituted alkoxy, —C(CH3)3, and X is hydroxyl, F, Cl, Br, optionally substituted alkoxy, are obtained in high yield and high purity by reacting phenylacetic acid derivatives of the formula (II) with phenols of the formula (III) in liquid hydrogen fluoride (HF).

Abstract: A food supplement for finishing hogs containing astaxanthin is described.

Abstract: Compounds of structure (I): including stereoisomers, tautomers and salts thereof, wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as defined herein. Such compounds are useful for the preparation of diarylpropane compounds. Methods for the preparation of compounds of structure (I) are also disclosed, as are methods employing compounds of structure (I) for the preparation of diarylpropanes.

Abstract: The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associates with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of an inhibitor is phloretin which was shown to inhibit osteoclast differentiation following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.

Abstract: The invention relates to a method for carrying out a chemical reaction for producing a target compound by heating in a reactor a reaction medium containing at least one first reactant, such that a chemical bond inside the first reactant or between the first and a second reactant is formed or modified. The reaction medium is brought into contact with a solid heating medium that can be warmed by electromagnetic induction and that is inside the reactor and is surrounded by the reaction medium. Said heating medium is heated by electromagnetic induction with the aid of an inductor and the target bond is formed from the first reactant or from the first and a second reactant and said target bond is separated from the heating medium.

Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.

Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Abstract: The present invention relates to a composition comprising an extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same, as an active ingredient. In particular, the extract and compounds have the excellent inhibitory effects on adipocyte differentiation, and thus can be used in a pharmaceutical composition and functional food for the prevention and treatment of lipid metabolism disorders.

Abstract: Antimicrobially active 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone of the following formula 1 is described, as is a method for producing this compound and the use thereof as an antimicrobial active ingredient.

Abstract: A subject-matter of the present invention is a novel process for the synthesis of (E)-stilbene derivatives targeted at obtaining in particular resveratrol and piceatannol.

Abstract: Compounds of formula (I): wherein R1 and R4 are OR7, R2 and R3 are H or OR7, with the proviso that when R2 is OR7 then R3 is H, and when R3 is OR7 then R2 is H; R5 and R6 are independently H, OH, or OR7 with the proviso that when R5 is OH, R6 is not OH; R7 is alkyl, aryl or arylalkyl; the drawing “” represents either a single or a double bond; or pharmaceutically acceptable salt(s) or prodrug(s) thereof. These compounds are useful of treatment, prophylaxis, amelioration, or defense against and/or prevention of hormonal dependent conditions, cancer, and diseases and conditions associated with oxidant stress.

Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.

Abstract: The present invention relates to the preparation and use of (colored) organic particles carrying electric charge as electrophoretic (image) displaying particles, to electrophoretic dispersions comprising the organic particles carrying electric charge, electrophoretic (image) devices (especially displays) comprising the colored organic particles carrying electric charge, to the novel functionalized particles, and to their use. The particles are obtainable according to a method represented by the reaction scheme as given in FIG. 1.

Abstract: Therapeutic method of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H or RACO wherein Ra is C1-10alkyl or an amino acid, R2 is H, OH or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c) or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (f) and B is (g) where R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, an

Abstract: The invention concerns the use of a deoxy hesperetin dihydrochalcone or a salt of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of a plurality of salts of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of deoxy hesperetin dihydrochalcone (I) and a salt or a plurality of salts of the deoxy hesperetin dihydrochalcone (I), to influence the strength of taste impressions of sweet-tasting, unpleasant-, in particular bitter-, tasting or both sweet- and unpleasant-, in particular bitter-, tasting substances or mixtures of substances.

Abstract: The present invention relates to a novel process for preparing ?-arylmethylcarbonyl compound of the formula (III), characterized in that aryl- and heteroarylacetic acids and derivatives thereof of the formula (I) are reacted with ?-halomethylcarbonyl compounds of the formula (II) in the presence of a palladium catalyst, of a phosphine ligand, of an inorganic base and of a phase transfer catalyst, optionally using an organic solvent.

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: A compound has Formula VIII where, X is —C(O)R, —C(O)OR, —CN, —NO2, —S(O)2R?, —P(O)(OR)2; each R is individually H, alkyl, or alkenyl; R? is alkyl or akenyl; R1 is aryl, alkenyl, arylalkenyl, heterocyclyl, or heteroaryl; and R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are individually H, alkoxy, or hydroxy. In some cases, X is NO2. Pharmaceutical compositions of the compound of Formula VIII with a pharmaceutically acceptable carrier may be prepared. The compounds may be used for inhibition of cyclooxygenase-2.

Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.

Abstract: The present invention relates to the use of compounds of the formula (I) where R stands for [lacuna] with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.

Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.